[S-18] Preclinical pathogenesis and therapy for neurodegeneration

[S-18-2] Preclinical pathogenesis of Parkinson's disease

Noriko Nishikawa (National Center of Neurology and Psychiatry, Japan)

Neurodegenerative diseases are characterized by a progressive decline of the motor and/or cognitive function caused by a selective loss of neurons within the central nervous system. Pathological changes at molecular and cellular levels precede the clinical onset by several years, underscoring a pressing need for initiation of interventions before the emergence of neurological symptoms. Using exquisite biomarkers, recent studies revealed the preclinical and prodromal progression of pathophysiology, as well as compensatory brain responses in several neurodegenerative diseases. This session aims to discuss the recent advancement of biomarker studies on presymptomatic subjects and the perspective on a preventive trial of disease-modifying therapies for devastating neurological disorders.

2018- present
Medical director, Department of Neurology, National Center of Neurology and Psychiatry
2012-2017
Associate professor, Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
2009-2012
Assistant Professor, Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
2005-2009
Clinical Fellow, Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
2000-2005
Resident, Department of Medicine (Neurology & Rheumatology), Shinshu University School of Medicine